Genomic study of metabolic fatty liver disease
Part of Digestive system, Genetic & congenital, Hormones & metabolism, Injuries & trauma clinical trials.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 70 years old.
- If you have MASLD, you need advanced liver scarring (stage 2 or more) or a liver cancer diagnosis.
- If you are in the control group, you must be a blood donor who is overweight or obese and have at least two of the following: high blood sugar/diabetes, high cholesterol, or high blood pressure.
- You cannot have chronic viral hepatitis (Hepatitis B or C) or other liver diseases like hemochromatosis or Wilson's disease.
- You must be enrolled in another study (SERENA or REASON) if you have MASLD.
- You must have had a liver biopsy or gallbladder removal for the MASLD group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study looks at fat buildup in the liver (fatty liver disease) in people with and without HIV. It uses blood tests to understand the liver's fat content and how it relates to HIV, which may help improve future care.
This study looks at how the liver responds to sugar given through a vein in obese patients with and without a fatty liver condition called MASLD. It may help doctors understand why some people develop liver problems from sugar and fat.
This study tests whether adding a liver stiffness measurement to a lifestyle program helps people with MASLD (a type of fatty liver disease) improve their liver health. It is designed for people who have fatty liver and at least one sign of metabolic syndrome, like high blood pressure or diabetes.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.